CAR T-cell therapy has revolutionized the treatment of hematologic malignancies, particularly in patients with CD19-positive B-cell malignancies, where CD19 CAR T-cell therapy has shown excellent efficacy (9–11). Here, CD19 is linked to hematologic disorder.